BrainsWay's Deep TMS Shows Strong Efficacy in PTSD-MDD Comorbidity Study
Event summary
- BrainsWay presented real-world data showing 83.5% response rate in PTSD symptoms for patients with comorbid PTSD and MDD using Deep TMS™.
- Study included 462 patients across 11 clinical sites, with mean symptom reduction of 52% in PCL-5 scores and 50% in PHQ-9 scores.
- Results presented at a leading industry conference by Colleen Hanlon, PhD, VP of Medical Affairs at BrainsWay.
- Deep TMS is not currently FDA-cleared for PTSD or comorbid PTSD-MDD treatment.
The big picture
This study represents the largest real-world analysis of Deep TMS in comorbid PTSD and MDD patients, addressing a significant unmet need in psychiatric care. The positive results strengthen BrainsWay's clinical evidence base while highlighting the challenges of navigating FDA clearance for new indications in complex mental health conditions.
What we're watching
- Regulatory Pathway
- Whether BrainsWay can secure FDA clearance for PTSD indications based on this real-world evidence.
- Clinical Adoption
- The pace at which clinicians will integrate Deep TMS into treatment protocols for comorbid psychiatric conditions.
- Competitive Positioning
- How these results position BrainsWay against other non-invasive brain stimulation technologies in the mental health space.